AU2003223304A1 - Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof - Google Patents

Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof

Info

Publication number
AU2003223304A1
AU2003223304A1 AU2003223304A AU2003223304A AU2003223304A1 AU 2003223304 A1 AU2003223304 A1 AU 2003223304A1 AU 2003223304 A AU2003223304 A AU 2003223304A AU 2003223304 A AU2003223304 A AU 2003223304A AU 2003223304 A1 AU2003223304 A1 AU 2003223304A1
Authority
AU
Australia
Prior art keywords
glycoside
apomorphine
analogs
orthoester
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003223304A
Other languages
English (en)
Inventor
Michael Holick
Halasya Ramanathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003223304A1 publication Critical patent/AU2003223304A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2003223304A 2002-03-19 2003-03-19 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof Abandoned AU2003223304A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36545402P 2002-03-19 2002-03-19
US60/365,454 2002-03-19
PCT/US2003/008448 WO2003080074A1 (en) 2002-03-19 2003-03-19 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof

Publications (1)

Publication Number Publication Date
AU2003223304A1 true AU2003223304A1 (en) 2003-10-08

Family

ID=28454658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003223304A Abandoned AU2003223304A1 (en) 2002-03-19 2003-03-19 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof

Country Status (9)

Country Link
US (1) US20060004190A1 (https=)
EP (1) EP1496915A1 (https=)
JP (1) JP2005526790A (https=)
KR (1) KR20050008658A (https=)
CN (1) CN1720054A (https=)
AU (1) AU2003223304A1 (https=)
BR (1) BR0308567A (https=)
CA (1) CA2479372A1 (https=)
WO (1) WO2003080074A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
PL2854764T3 (pl) 2012-06-05 2019-07-31 Neuroderm Ltd Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania
CA2930410A1 (en) 2013-11-11 2015-05-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
BR112017013749A2 (en) * 2014-12-23 2018-03-27 Neuroderm Ltd apomorphine crystal forms and their uses
JP7320507B2 (ja) 2017-11-24 2023-08-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
CN114773409B (zh) * 2022-04-27 2023-12-15 江西艾立斯特生物科技有限公司 一种2,3,4,6-四-o-乙酰基-吡喃葡萄糖的制备方法
US20250361252A1 (en) 2022-06-15 2025-11-27 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785014A (en) * 1985-06-07 1988-11-15 Yale University Use of clonidine in memory enhancement
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
JP3310982B2 (ja) * 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO1999065563A1 (en) * 1998-06-19 1999-12-23 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
BR0109515A (pt) * 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso

Also Published As

Publication number Publication date
US20060004190A1 (en) 2006-01-05
WO2003080074A1 (en) 2003-10-02
KR20050008658A (ko) 2005-01-21
CN1720054A (zh) 2006-01-11
EP1496915A1 (en) 2005-01-19
CA2479372A1 (en) 2003-10-02
JP2005526790A (ja) 2005-09-08
BR0308567A (pt) 2007-01-09

Similar Documents

Publication Publication Date Title
AU2003223304A1 (en) Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
AU2003257546A1 (en) Novel composition containing acyl group
AU2003225551A1 (en) Synthesis of 2h- and 13c- substituted dithianes
AU2002951346A0 (en) Diagnosis of ovarian cancer
AU2003282533A1 (en) Improvements to showerheads
AU2003301654A1 (en) Stabilized composition
AU2003292263A1 (en) Use of substituted 2-phenylbenzimidazoles as medicaments
AU2003279690A1 (en) Synthesis of purine derivatives
AU2003249713A1 (en) 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
AU2003271037A1 (en) The extractive of aweto and process for its preparation and uses
AUPS143402A0 (en) Anomeric derivatives of monosaccharides
AU2003284457A1 (en) Beta-1,4-MANNOBIOSE-CONTAINING COMPOSITION
AUPS239302A0 (en) Improvements to tow-bars
AU2003217791A1 (en) Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
AU2003279392A1 (en) Pharmaceutical compositions of azithromycin
AU2003265373A1 (en) Preparation of aztreonam
AU2003229459A1 (en) Methods of using thiazolidinedithione derivatives
AU2002335304A1 (en) The use of berberine as insulin sensitizer
AU2003219507A1 (en) Process for the preparation of highly pure torsemide
AU2003298725A1 (en) Preparation of metallotexaphyrins
AU2003275713A1 (en) Use of sglt homolog
AU2003225642A1 (en) Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs
AU2003253701A1 (en) 11-c-substituted derivatives of clarithromycin
AU2003238034A1 (en) Novel use of imidazotriazinones
AU2003250716A1 (en) Continuous production of couscous

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase